Correspondence on ‘Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort’

Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review

“…Thirty-one studies reported immunogenicity in 4680 patients with inflammatory immune-mediated diseases ( Table S6 ) [ 27 , 28 , 32 , 36 , 37 , 39 , [45] , [46] , [47] , 50 , 51 , 54 , 55 , 82 , [161] , [162] , [163] , [164] , [165] , [166] , [167] , [168] , [169] , [170] , [171] , [172] , [173] , [174] , [175] , [176] , [177] , [178] ]. Main represented groups included rheumatoid arthritis ( n = 665), inflammatory bowel diseases ( n = 476) and multiple sclerosis ( n = 231).…”

“…Main represented groups included rheumatoid arthritis ( n = 665), inflammatory bowel diseases ( n = 476) and multiple sclerosis ( n = 231). Twenty of those studies had a control group [ 32 , 37 , [45] , [46] , [47] , 50 , 51 , 55 , [161] , [162] , [163] , [164] , 166 , 167 , 169 , 171 , 172 , 174 , 177 , 178 ] ( n = 1609), among which 16 participants failed to mount a post-vaccine antibody response [ 47 , 50 , 51 , 55 , 163 , 164 ].…”

“…found high rates (respectively 47% and 50%) in patients with multiple sclerosis (MS) [ 164 , 168 ]. Six studies tested participants' sera with neutralization assays [ 32 , 37 , 51 , 163 , 172 , 174 ], one tested neutralization on a SARS-CoV-2 spike protein bearing the N501Y mutation (present in the alpha variant) [ 32 ]. Two studies provided non-response rates which were either the same as with anti-S IgG assay (0%, 0/26 [ 172 ]) or higher (44%, 375/859 vs. 29%, 245/859 with the anti-S assay [ 51 ]).…”

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination

“…Initial immunogenicity data available for at-risk subgroups showed a high proportion of non-responders and low antibody responses to the SARS-CoV-2 spike protein in patients who received solid-organ transplantation [18], patients treated for solid cancer [19], or in patients with ongoing hemodialysis [20]. In contrast, the available studies to date show that a full course of mRNA vaccine in patients with IMID elicit a response in 78-100% of subjects [21], showing reduced serum antibody IgG titers and serum neutralizing activity as compared to healthy controls [10,13,14,[22][23][24]. Reduced humoral and cellular immune response (CD8 +) to COVID-19 mRNA vaccines were found by Haberman et al in IMID treated with methotrexate and by Mahil et al in psoriasis (47% and 62% responders, respectively) [23,25], although this finding has not been confirmed in our and other studies (> 80% responders) [14,21,22,26].…”

Evaluation of antibody response to BNT162b2 mRNA COVID-19 vaccine in patients affected by immune-mediated inflammatory diseases up to 5 months after vaccination

“…Initial immunogenicity data available for at-risk subgroups showed a high proportion of non-responders and low antibody responses to the SARS-CoV-2 spike protein in patients who received solid-organ transplantation [13], patients treated for solid cancer [14], or in patients with ongoing hemodialysis [15]. In contrast, the available studies to date show that a full course of mRNA vaccine in patients with IMID elicit a response in 78-100% of subjects, showing reduced serum antibody IgG titers and serum neutralizing activity as compared to healthy controls [16][17][18][19][20][21]. Even with limitations due to different assays and thresholds used across the available studies, the vaccine elicited responses is largely indicative of a considerable immunogenicity.…”